loader image
Friday, August 29, 2025
102 F
McAllen
- Advertisement -

PREVENTION of COVID-19 in High-risk Subjects Using Long-acting Antibodies

Translate to Spanish or other 102 languages!

DHR Health Institute for Research and Development is initiating an innovative clinical study to prevent COVID-19 in high-risk patients. Image of illustration purposes.
DHR Health Institute for Research and Development is initiating an innovative clinical study to prevent COVID-19 in high-risk patients. Image of illustration purposes.

Mega Doctor News

- Advertisement -

Edinburg, TX – DHR Health Institute for Research and Development is initiating an innovative clinical study to prevent COVID-19 in high-risk patients.

This is the first such study that is designed to provide passive immunity to patients who have immunocompromised status and cannot mount a robust immune response when infected with the SARS-CoV-2 virus.

On December 8, 2021, the U.S. Food and Drug Administration issued an Emergency Use Authorization allowing the use of AstraZeneca’s long-acting antibody EVUSHELD to be used for prevention of COVID-19 in subjects 12 years and older with moderate to severe immunocompromised status before exposure to the virus.

- Advertisement -

“For various medical reasons, over seven million people in the United States remain vulnerable to moderate to severe infection with the SARS-CoV-2 virus” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “These are patients who are receiving chemotherapy for cancers, immunosuppressive drugs following transplantation and/or for conditions such as rheumatoid arthritis and lupus”.

“These patients despite vaccination, are unable to generate and sustain satisfactory immune response even after receiving booster doses of COVID-19 vaccine” said Rao “Treatment with this long-acting antibody will provide them with protection against SARS-CoV-2 virus for up to 6-9 months”.

If you or your patient is interested to participate in this study, please call 956-342-4896.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Paxton Secures $720M from Drug Manufacturers for their Role in the Catastrophic Opioid Epidemic

Mega Doctor News AUSTIN – Attorney General Ken Paxton secured a new opioid...

Common Painkillers Linked to Antibiotic Resistance

Mega Doctor News By University of South Australia Newswise — Ibuprofen and paracetamol are common...

New 5% Income Floor Limits Charitable Deductions for Itemizers

Mega Doctor News Texas Border Business / Mega Doctor News The “One, Big,...

New Tax Law Expands Charitable Deductions for Non-Itemizers

Mega Doctor News Texas Border Business / Mega Doctor News The “One, Big,...
- Advertisement -
×